JF

John Furey

Chief Executive Officer

Imvax, Inc.

Philadelphia, Pennsylvania


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Imvax, Inc.
Industry
research
Employees
37.0
Seniority
C suite
Annual Revenue
1200000.0
Total Funding
278457959.0
Latest Funding
Other

Technologies

Outlook Microsoft Office 365 Google Cloud Hosting Mobile Friendly Google Tag Manager Nginx Bootstrap Framework Vimeo Gravity Forms WordPress.org

Keywords

immunotherapy biotechnology autologous vaccines biopharmaceuticals glioblastoma multiforme clinical trials research biotechnology research goldspire platform tumor-derived treatments personalized medicine solid tumors glioblastoma igv-001 biologic-device combination antigen signature innate immunity adaptive immunity chemotherapy radiation therapy biodiffusion chambers immune response cancer treatment advanced oncology phase 2 trial autoimmune tumors phase 1 trials whole tumor vaccine cancer immunotherapy oncology research therapeutic pipeline tumor cell immunogenicity antisense oligonucleotide tumor antigen recognition immuno-oncology patient care cancer patient advocacy safety data phase 2 development clinical trial enrollment fda fast track designation survival analysis progression-free survival overall survival innovative therapies treatment options research & development life sciences healthcare innovation tumor processing quality control in biopharma patient-centered care healthcare investments solid tumor vaccines health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans